Welcome to the CCO Site

Thank you for your interest in CCO content. As a guest, please complete the following information fields. These data help ensure our continued delivery of impactful education. 

Become a member (or login)? Member benefits include accreditation certificates, downloadable slides, and decision support tools.

Submit

Smarter. Stronger. Together: Educating Providers and Patients to Optimize the Use of Targeted Oral Therapies for HR+/HER2- Breast Cancer
  • CME
  • CE

Credits Available
Physicians: maximum of 1.0 AMA PRA Category 1 Credit™
Registered Nurses: 1.0 Nursing contact hour
Pharmacists: 1.0 contact hour (0.1 CEUs)
Released: April 8, 2021 Expiration: April 7, 2022
Start Activity
Produced in collaboration with
Supported by an educational grant from
Lilly
Matthew P. Goetz, MD
Sara Hurvitz, MD, FACP
Joyce O'Shaughnessy, MD

Learning Objectives

Upon completion of this activity, participants should be able to:
  • Address gaps in patient–provider knowledge and perceptions about targeted oral therapies for HR+/HER2- EBC and ABC
  • Foster collaborative discussions between patients/caregivers and providers on guidelines and recent clinical evidence to guide personalized treatment planning for HR+/HER2- EBC and ABC
  • Recognize and manage adverse events associated with approved CDK4/6 and PI3K inhibitors

Information on this Educational Activity

Faculty

Joyce O'Shaughnessy, MD

Celebrating Women Chair in Breast Cancer Research
Director, Breast Cancer Research Program
Baylor University Medical Center
Texas Oncology
US Oncology Network
Dallas, Texas

Joyce O’Shaughnessy, MD, has disclosed that she has received honoraria for consulting and/or advisory boards from AbbVie, Agendia, Amgen Biotechnology, AstraZeneca, Bristol-Myers Squibb, Celgene, Eisai, G1 Therapeutics, Genentech, Immunomedics, Ipsen, Jounce, Lilly, Merck, Myriad, Novartis, Ondonate, Pfizer, Puma Biotechnology, Roche, Seattle Genetics, and Syndax.
Sara Hurvitz, MD, FACP

Professor of Medicine
Director, Breast Oncology Program
Division of Hematology-Oncology
Department of Medicine
David Geffen School of Medicine at UCLA
Los Angeles, California

Sara Hurvitz, MD, FACP, has disclosed that she has received funds for research support from Ambrx, Amgen, AstraZeneca, Arvinas, Bayer, Daiichi Sankyo, Dignitana, Genentech/Roche, Gilead Sciences, GlaxoSmithKline, Immunomedics, Lilly, MacroGenics, Novartis, Pfizer, OBI Pharma, Phoenix Molecular Designs, Pieris, PUMA, Radius, Sanofi, Seattle Genetics, and Zymeworks.
Matthew P. Goetz, MD

Professor of Oncology and Pharmacology
Director, Mayo Breast Cancer SPORE
Co-PI, Women's Cancer Program
Department of Medical Oncology
Mayo Clinic
Rochester, Minnesota

Matthew P. Goetz, MD, has disclosed that he has received consulting fees paid to his institution from Biotheranostics, Biovica, Context Pharm, Eagle Pharmaceuticals, Lilly, Novartis, Pfizer, and Sermonix and has received funds for research support paid to his institution from Lilly, Pfizer, and Sermonix.

Staff

Kristen Rosenthal, PhD

Senior Scientific Director

Kristen Rosenthal, PhD, has no relevant conflicts of interest to report.
Megan Cartwright, PhD

Senior Clinical Editor

Megan Cartwright, PhD, has no relevant conflicts of interest to report.
Shara Pantry, PhD
Shara Pantry, PhD, has no relevant conflicts of interest to report.
Timothy A. Quill, PhD

Associate Director, Scientific Services

Timothy A. Quill, PhD, has no relevant conflicts of interest to report.
Kevin Obholz, PhD

Senior Director, Educational Strategy

Kevin Obholz, PhD, has no relevant conflicts of interest to report.
Jason Everly, PharmD

Director, Program Development and Educational Impact

Jason Everly, PharmD, BCOP, CHCP, has no relevant conflicts of interest to report.
Kristi Kay Orbaugh, RN, MSN, RNP, AOCN

Adult Oncology Nurse Practitioner
Community Hospital Oncology Physicians
Indianapolis, Indiana

Kristi Orbaugh, MSN, RNP, AOCN, has no relevant conflicts of interest to report.

Target Audience

This educational program is intended for oncologists, advanced practice clinicians, oncology nurses, navigators, pharmacists, and other supportive services who care for patients with HR+/HER2- EBC and ABC.

Goal

The goal of this activity is to improve the competence and performance of learners in applying practice-changing clinical data and expert recommendations regarding the use of current and emerging endocrine and targeted therapies in the management of patients with HR-positive/HER2-negative breast cancer.

Accreditation

Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education

Credit Designation

CCO designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nursing Continuing Education

Credit Designation

The maximum number of hours awarded for this Continuing Nursing Education activity is 1.0 contact hour.

Continuing Pharmacy Education

Credit Designation

CCO designates this continuing education activity for 1.0 contact hour (0.1 CEUs) of the Accreditation Council for Pharmacy Education. Universal Activity Number - JA4008176-0000-21-075-H01-P.

Type of Activity: Knowledge

Upon successfully completing the post-test with a score of 65% or better and the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 60 days.

Program Medium

This program has been made available online.

Instructions for Credit

Participation in this self-study activity should be completed in approximately 1.0 hours. To successfully complete this activity and receive credit, participants must follow these steps during the period from April 08, 2021, through April 07, 2022:

1. Register online at http://www.clinicaloptions.com.
2. Read the target audience, learning objectives, and faculty disclosures.
3. Study the educational activity online or printed out.
4. Submit answers to the posttest questions and evaluation questions online.

You must receive a test score of at least 65% and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the posttest confirmation page. Records of all CME/CE activities completed can be found on the "CME/CE Manager" page. There are no costs/fees for this activity.

Smarter. Stronger. Together: Educating Providers and Patients to Optimize the Use of Targeted Oral Therapies for HR+/HER2- Breast Cancer
  • CME
  • CE

Source: Smarter. Stronger. Together: Educating Providers and Patients to Optimize the Use of Targeted Oral Therapies for HR+/HER2- Breast Cancer
Loading...
Expert faculty review the use of targeted oral therapies for HR+/HER2- breast cancer.
Matthew P. Goetz, MD
Sara Hurvitz, MD, FACP
Joyce O'Shaughnessy, MD
Physicians: maximum of 1.0 AMA PRA Category 1 Credit™
Registered Nurses: 1.0 Nursing contact hour
Pharmacists: 1.0 contact hour (0.1 CEUs)
Released: April 8, 2021 Expiration: April 7, 2022

Related Content

Prof. Dr. Arndt Hartmann Released: April 9, 2021

Experts discuss their practices with CDK4/6 and PI3K inhibitors for patients with breast cancer in today’s clinic from Clinical Care Options (CCO)

Matthew P. Goetz, MD Sara Hurvitz, MD, FACP Joyce O'Shaughnessy, MD Released: March 23, 2021

Downloadable short slideset from CCO on the use of CDK4/6 and PIK3CA inhibitors for patients with HR+/HER2 breast cancer.

Matthew P. Goetz, MD Sara Hurvitz, MD, FACP Joyce O'Shaughnessy, MD Released: March 9, 2021

Expert commentary with a European perspective on key studies from 2020 SABCS, from Clinical Care Options (CCO)

Javier Cortes, MD, PhD Released: March 8, 2021
Produced in collaboration with
Supported by an educational grant from
Lilly

For further information concerning Lilly grant funding,
visit www.lillygrantoffice.com.

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue